Lead Product(s) : Nitroxoline
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Centers for Disease Control and Prevention
Deal Size : Undisclosed
Deal Type : Agreement
Asieris, CDC Sign Agreement for APL-1202 Under Expanded Access Program
Details : Asieris has entered into an agreement to collaborate with the CDC in the US on APL-1202 (nitroxoline), It is being investigated for the treatment of FLA infections.
Product Name : APL-1202
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 06, 2025
Lead Product(s) : Nitroxoline
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Centers for Disease Control and Prevention
Deal Size : Undisclosed
Deal Type : Agreement
Reset All
